Astani A., Reichling J., Schnitzler P. Comparative study on the
antiviral activity of selected monoterpenes derived from essential oils.
Phytother Res. 2010 24(5):673-9. doi:
10.1002/ptr.2955.
Berger W. Aerosol devices and asthma therapy. Curr Drug Deliv. 2009
Jan;6(1):38-49. DOI: 10.2174/156720109787048203
Bhowal M., Gopal M. Eucalyptol: safety and pharmacological profile. J
Pharm Sci 5 125-131. DOI:10.5530/rjps.2015.4.2
Condos R, Hull FP, Schluger NW, Rom WN, Smaldone GC. Regional deposition
of aerosolized interferon-gamma in pulmonary tuberculosis. Chest.
2004;125:2146–2155. DOI:10.1378/chest.125.6.2146
Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant
pulmonary tuberculosis with interferon-γ via
aerosol. Lancet. 1997;349:1513–1515. doi:
10.1016/S0140-6736(96)12273-X.
Debs R.J., Montgomery A.B., Brunette E.N., De Bruin M., Shanley J.D.
Aerosol Administration of Antiviral Agents to Treat Lung Infection Due
to Murine Cytomegalovirus. J Infect Dis. 1988 Feb;157(2):327-3. DOI:
10.1093/infdis/157.2.327
Dehshikh A.B., Sourestani M.M., Dehsheikh P.B., Mottaghipisheh j., et
al. Monoterpenes: Essential Oil Components with Valuable Features. Mini
Rev Med Chem. 2020 Jan 22. doi: 10.2174/1389557520666200122144703.
Dent AG, Sutedja TG, Zimmerman PV. Exhaled breath analysis for lung
cancer. J
Thorac Dis. 2013 Oct;5 Suppl 5:S540-50. doi:
10.3978/j.issn.2072-1439.2013.08.44.
Diot P., Plantier L. A New Era for Ribavirin Aerosols to Treat
Respiratory Syncitial Virus Infections in Immunocompromised Patients?
Respir Care. 2016; 61(5):714-5. doi: 10.4187/respcare.04797.
Fischer J, Dethlefsen U.
Efficacy of cineole in patients suffering from acute bronchitis:
a placebo-controlled double-blindtrial.Cough. 2013
Nov 21;9(1):25. doi: 10.1186/1745-9974-9-25.
Galan D.M., Ezeudu N.E., Garcia J., Geronimo C.A., et al. Eucalyptol
(1,8-cineole): an underutilized ally in respiratory disorders? JOURNAL
OF ESSENTIAL OIL RESEARCH
Gao, J., Tian, Z., Yang, X., 2020. Breakthrough: chloroquine phosphate
has shown apparent efficacy in treatment of COVID-19 associated
pneumonia in clinical studies. Biosci Trends. 2020; 16;14(1):72-73. doi:
10.5582/bst.2020.01047.
Greiner JF, Müller J, Zeuner MT, Hauser S, et al. 1,8-Cineol inhibits
nuclear translocation of NF-κB p65 and NF-κB-dependent transcriptional
activity.Biochim
Biophys Acta. 2013;1833(12):2866-2878. doi:
10.1016/j.bbamcr.2013.07.001.
Jiang S. Don’t rush to deploy COVID-19 vaccines and drugs without
sufficient safety guarantees.
Nature. 2020
Mar;579(7799):321. doi: 10.1038/d41586-020-00751-9.
Jin YH, Cai L, Cheng ZS, Cheng H, et al. A rapid advice guideline for
the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV)
infected pneumonia (standard version). Mil Med Res. 2020 Feb 6;7(1):4.
doi: 10.1186/s40779-020-0233-6.
Juergens UR, Stöber M, Schmidt-Schilling L, Kleuver T, et al.,
Antiinflammatory effects of eucalyptol (1.8-cineole) in bronchial
asthma: inhibition of arachidonic acid metabolism in human blood
monocytes ex vivo. European Journal of Medical Research, Eur J Med
Res. 1998 Sep 17;3(9):407-12.
Juergens UR1, Dethlefsen U, Steinkamp G, Gillissen A,
et al. Anti-inflammatory activity of 1.8-cineol (eucalyptol) in
bronchial asthma: a double-blind placebo-controlled trial. Respir
Med. 2003 Mar;97(3):250-6.
Kawai N, Ikematsu H, Iwaki N, Maeda T, et al. A comparison of
the effectiveness of zanamivir and oseltamivir for
the treatment of influenza A and B.J
Infect. 2008 Jan;56(1):51-7. DOI: 10.1016/j.jinf.2007.09.002
Kohlert C, van Rensen I, März R, Schindler G, et al. Bioavailability and
Pharmacokinetics of Natural Volatile Terpenes in Animals and Humans.
Planta Med. 2000 Aug;66(6):495-505.
Kozioł A, Stryjewska A, Librowski T, Sałat K, et al. An Overview of the
Pharmacological Properties and Potential Applications of Natural
Monoterpenes. Mini Rev Med Chem. 2014;14(14):1156-68.
Leiva-Juarez MM, Kirkpatrick CT, Gilbert BE, Scott B, et al. Combined
aerosolized Toll-like receptor ligands are an effective therapeutic
agent against influenza pneumonia when co-administered with oseltamivir.
Eur J Pharmacol. 2018; 5;818:191-197. doi: 10.1016/j.ejphar.2017.10.035
Li G., De Clercq E. Therapeutic options for the 2019 novel coronavirus
(2019-nCoV). Nat Rev Drug Discov. 2020; 19(3):149-150. doi:
10.1038/d41573-020-00016-0.
Lin MH, Moses DC, Hsieh CH, Cheng SC., et al. Disulfiram can inhibit
MERS and SARS coronavirus papain-like proteases via different modes.
Antiviral Res. 2018; 150:155-163. doi: 10.1016/j.antiviral.2017.12.015.
Fischer J, Dethlefsen U. Efficacy of cineole in patients suffering from
acute bronchitis: a placebo-controlled double-blind trial. Cough 2013;
21;9(1):25. doi: 10.1186/1745-9974-9-25.
Maxmen A. More than 80 clinical trials launch to test coronavirus
treatments. Nature. 2020 Feb;578(7795):347-348. doi:
10.1038/d41586-020-00444-3.
Millard J, Ugarte-Gil C, Moore DA. Multidrug resistant tuberculosis.
BMJ. 2015; 26;350:h882. doi: 10.1136/bmj.h882.
Miyazawa M, Shindo M, Shimada T. Oxidation of 1, 8-cineole, the
monoterpene cyclic ether originated from Eucalyptus polybractea, by
cytochrome P450 3A enzymes in rat and human liver microsomes. Drug Metab
Dispos. 2001; 29: 200-205.
Moss RB, Mayer-Hamblett N, Wagener J, Daines C, et al. Randomized,
double-blind, placebo-controlled, dose-escalating study of aerosolized
interferon gamma-1b in patients with mild to moderate cystic fibrosis
lung disease.Pediatr
Pulmonol. 2005 Mar;39(3):209-18. DOI:10.1002/ppul.20152
Peng AW, Milleri S, Stein DS. Direct measurement of the anti-influenza
agent zanamivir in the respiratory tract following inhalation.
Antimicrob Agents Chemother. 2000; 44(7):1974-6.
Prasanthi D, Lakshmi PK. Terpenes: effect of lipophilicity in enhancing
transdermal delivery of alfuzosin hydrochloride. J Adv Pharm Technol Res
2012;3(4):216-23. doi: 10.4103/2231-4040.104712.
Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020 Mar
13. pii: S0140-6736(20)30627-9. doi: 10.1016/S0140-6736(20)30627-9.